MPN
Myeloproliferative neoplasms (MPNs) are rare cancers and include diseases of the blood and bone marrow. MPNs involve dysregulation at the multipotent hematopoietic stem cell (CD34). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Myelofibrosis Awareness Day is marked on September 20th each year.
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea.
The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285.
Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave.
The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.
Researchers presented data from the randomized withdrawal phase of the study at the SOHO Annual Meeting.
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Dr. Harrison discusses survey results from the LANDMARK survey in patients with polycythemia vera and their physicians.
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
The median JAK2 mutant allele burden at baseline significantly differed among MPN subsets.
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Dr. Sekeres also speaks about his time on the FDA ODAC and his latest book, titled "Drugs and the FDA."
Dr. Krecak presented the research during the 2023 EHA Congress.
Spleen volume reduction predicts OS in patients with myelofibrosis who are taking pacritinib.
A new study is exploring add-on treatment of CK0804 in patients with myelofibrosis and suboptimal response to ruxolitinib.
The phase II MANIFEST study suggested that pelabresib could be beneficial in myelofibrosis.
The study indirectly compared safety outcomes from phase II and phase III trials of momelotinib and fedratinib.
The median time to achieving the first spleen volume reduction of at least 35% from baseline was 12 weeks.
Prithviraj Bose, MD, and colleagues presented results of the study during the 2023 ASCO Annual Meeting.
The authors concluded that treatment with INCB057643 monotherapy was generally well tolerated.
The case-control study used information from the Veterans Affairs Informatics and Computing Infrastructure database.
The study is designed to evaluate the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adults with ET.
Luspatercept-aamt demonstrated “favorable outcomes” compared with epoetin alfa across common mutations in MDS.
Researchers followed the patients for three years after their final dose of luspatercept.
Jakatinib may be a new effective treatment option for patients with myelofibrosis.
Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts.
Selinexor plus ruxolitinib was effective in certain subgroups of patients with myelofibrosis.
In patients with Afib, MPNs are linked to an increased risk of hospital readmissions for bleeding and arterial thrombosis.
The pooled analysis set included patients from both arms of the intent-to-treat populations in SIMPLIFY-1 and SIMPLIFY-2.
The trial will enroll certain patients who had an "inadequate response” to ruxolitinib alone.
The main aim of treatment is preventing thrombotic complications.
Dr. Tefferi discusses risk stratification systems for primary myelofibrosis, transplant considerations, and more.
They detected mutated TP53 in 49 (13%) patients, with 30 of those patients showing a multihit configuration.
The model was developed and validated using data from the CIBMTR and EBMT registries.
The study evaluated longitudinal symptom score changes to “complement the interpretation of the landmark symptom ...
Planning for a phase III trial of the combination is underway.
Jan Bewersdorf, MD, discusses a current ongoing phase I study investigating the combination of ruxolitinib and abemaciclib.
Advertisement
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
